APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ondansetron

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Ondansetron, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable ondansetron performance?

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Industry Growth & Trends

Global Ondansetron Industry Growth and Trends Forecast to 2032

15 January 2026121 pages

Choose your research edition.

Industry ResearchOndansetron Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Ondansetron Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Ondansetron Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ondansetron Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Ondansetron Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

Read the full market overview

The global Ondansetron market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ondansetron include Sun Pharmaceuticals, Sandoz, Qilu Pharmaceutical, Fuan Pharmaceutical, PKU HealthCare, Wockhardt, Aelida Healthcare, Beijing Sciecure Pharmaceutical and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Ondansetron market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Ondansetron market size, estimates, and forecasts are presented in terms of sales volume (kg) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Ondansetron market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Ondansetron.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Ondansetron market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Ondansetron Market by Company

Sun Pharmaceuticals

Sandoz

Qilu Pharmaceutical

Fuan Pharmaceutical

PKU HealthCare

Wockhardt

Aelida Healthcare

Beijing Sciecure Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Fosun Pharma

Harbin Medisan

CTX Lifesciences

Pfizer

Viatris

Dr. Reddy's Laboratories

Aurobindo Pharma

Zydus Lifesciences

Lupin

Hikma Pharmaceuticals

Fresenius Kabi

Baxter Pharmaceuticals

Ondansetron Segment by Type

Tablets (including ODT)

Injection

ODF/OSF

Other

Ondansetron Segment by Application

Hospital pharmacies

Retail pharmacies

Online pharmacies

Ondansetron Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ondansetron and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ondansetron manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Ondansetron in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Tablets (including ODT) Table 2. Major Company of Injection Table 3. Major Company of ODF/OSF Table 4. Major Company of Other Table 5. Global Ondansetron Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Ondansetron Sales by Type (2021-2026) & (kg) Table 7. Global Ondansetron Sales Market Share in Volume by Type (2021-2026) Table 8. Global Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 9. Global Ondansetron Sales Market Share in Value by Type (2021-2026) Table 10. Global Ondansetron Price by Type (2021-2026) & (USD/g) Table 11. Global Ondansetron Sales by Type (2027-2032) & (kg) Table 12. Global Ondansetron Sales Market Share in Volume by Type (2027-2032) Table 13. Global Ondansetron Sales by Type (2027-2032) & (US$ Million) Table 14. Global Ondansetron Sales Market Share in Value by Type (2027-2032) Table 15. Global Ondansetron Price by Type (2027-2032) & (USD/g) Table 16. North America Ondansetron Sales by Type (2021-2026) & (kg) Table 17. North America Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Ondansetron Sales by Type (2021-2026) & (kg) Table 19. Europe Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Ondansetron Sales by Type (2021-2026) & (kg) Table 21. Asia-Pacific Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Ondansetron Sales by Type (2021-2026) & (kg) Table 23. Latin America Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Ondansetron Sales by Type (2021-2026) & (kg) Table 25. Middle East and Africa Ondansetron Sales by Type (2021-2026) & (US$ Million) Table 26. Ondansetron Industry Trends Table 27. Ondansetron Industry Drivers Table 28. Ondansetron Industry Opportunities and Challenges Table 29. Ondansetron Industry Restraints Table 30. Global Ondansetron Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Ondansetron Revenue Market Share by Company (2021-2026) Table 32. Global Ondansetron Sales by Company (2021-2026) & (kg) Table 33. Global Ondansetron Sales Share by Company (2021-2026) Table 34. Global Ondansetron Market Price by Company (2021-2026) & (USD/g) Table 35. Global Ondansetron Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Ondansetron Major Company Production Sites and Headquarters Table 37. Global Ondansetron Company, Product Type & Application Table 38. Global Ondansetron Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Ondansetron by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Ondansetron Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Ondansetron Sales by Region (2021-2026) & (kg) Table 43. Global Ondansetron Sales Market Share in Volume by Region (2021-2026) Table 44. Global Ondansetron Sales by Region (2021-2026) & (US$ Million) Table 45. Global Ondansetron Sales Market Share in Value by Region (2021-2026) Table 46. Global Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 47. Global Ondansetron Sales by Region (2027-2032) & (kg) Table 48. Global Ondansetron Sales Market Share in Volume by Region (2027-2032) Table 49. Global Ondansetron Sales by Region (2027-2032) & (US$ Million) Table 50. Global Ondansetron Sales Market Share in Value by Region (2027-2032) Table 51. Global Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2027-2032) Table 52. Global Ondansetron Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Ondansetron Sales by Application (2021-2026) & (kg) Table 54. Global Ondansetron Sales Market Share in Volume by Application (2021-2026) Table 55. Global Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 56. Global Ondansetron Sales Market Share in Value by Application (2021-2026) Table 57. Global Ondansetron Price by Application (2021-2026) & (USD/g) Table 58. Global Ondansetron Sales by Application (2027-2032) & (kg) Table 59. Global Ondansetron Sales Market Share in Volume by Application (2027-2032) Table 60. Global Ondansetron Sales by Application (2027-2032) & (US$ Million) Table 61. Global Ondansetron Sales Market Share in Value by Application (2027-2032) Table 62. Global Ondansetron Price by Application (2027-2032) & (USD/g) Table 63. North America Ondansetron Sales by Application (2021-2026) & (kg) Table 64. North America Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Ondansetron Sales by Application (2021-2026) & (kg) Table 66. Europe Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Ondansetron Sales by Application (2021-2026) & (kg) Table 68. Asia-Pacific Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Ondansetron Sales by Application (2021-2026) & (kg) Table 70. Latin America Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Ondansetron Sales by Application (2021-2026) & (kg) Table 72. Middle East and Africa Ondansetron Sales by Application (2021-2026) & (US$ Million) Table 73. Sun Pharmaceuticals Company Information Table 74. Sun Pharmaceuticals Business Overview Table 75. Sun Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 76. Sun Pharmaceuticals Ondansetron Product Portfolio Table 77. Sun Pharmaceuticals Recent Development Table 78. Sandoz Company Information Table 79. Sandoz Business Overview Table 80. Sandoz Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 81. Sandoz Ondansetron Product Portfolio Table 82. Sandoz Recent Development Table 83. Qilu Pharmaceutical Company Information Table 84. Qilu Pharmaceutical Business Overview Table 85. Qilu Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 86. Qilu Pharmaceutical Ondansetron Product Portfolio Table 87. Qilu Pharmaceutical Recent Development Table 88. Fuan Pharmaceutical Company Information Table 89. Fuan Pharmaceutical Business Overview Table 90. Fuan Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 91. Fuan Pharmaceutical Ondansetron Product Portfolio Table 92. Fuan Pharmaceutical Recent Development Table 93. PKU HealthCare Company Information Table 94. PKU HealthCare Business Overview Table 95. PKU HealthCare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 96. PKU HealthCare Ondansetron Product Portfolio Table 97. PKU HealthCare Recent Development Table 98. Wockhardt Company Information Table 99. Wockhardt Business Overview Table 100. Wockhardt Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 101. Wockhardt Ondansetron Product Portfolio Table 102. Wockhardt Recent Development Table 103. Aelida Healthcare Company Information Table 104. Aelida Healthcare Business Overview Table 105. Aelida Healthcare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 106. Aelida Healthcare Ondansetron Product Portfolio Table 107. Aelida Healthcare Recent Development Table 108. Beijing Sciecure Pharmaceutical Company Information Table 109. Beijing Sciecure Pharmaceutical Business Overview Table 110. Beijing Sciecure Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 111. Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio Table 112. Beijing Sciecure Pharmaceutical Recent Development Table 113. Jiangsu Hengrui Pharmaceuticals Company Information Table 114. Jiangsu Hengrui Pharmaceuticals Business Overview Table 115. Jiangsu Hengrui Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 116. Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio Table 117. Jiangsu Hengrui Pharmaceuticals Recent Development Table 118. Fosun Pharma Company Information Table 119. Fosun Pharma Business Overview Table 120. Fosun Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 121. Fosun Pharma Ondansetron Product Portfolio Table 122. Fosun Pharma Recent Development Table 123. Harbin Medisan Company Information Table 124. Harbin Medisan Business Overview Table 125. Harbin Medisan Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 126. Harbin Medisan Ondansetron Product Portfolio Table 127. Harbin Medisan Recent Development Table 128. CTX Lifesciences Company Information Table 129. CTX Lifesciences Business Overview Table 130. CTX Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 131. CTX Lifesciences Ondansetron Product Portfolio Table 132. CTX Lifesciences Recent Development Table 133. Pfizer Company Information Table 134. Pfizer Business Overview Table 135. Pfizer Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 136. Pfizer Ondansetron Product Portfolio Table 137. Pfizer Recent Development Table 138. Viatris Company Information Table 139. Viatris Business Overview Table 140. Viatris Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 141. Viatris Ondansetron Product Portfolio Table 142. Viatris Recent Development Table 143. Dr. Reddy's Laboratories Company Information Table 144. Dr. Reddy's Laboratories Business Overview Table 145. Dr. Reddy's Laboratories Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 146. Dr. Reddy's Laboratories Ondansetron Product Portfolio Table 147. Dr. Reddy's Laboratories Recent Development Table 148. Aurobindo Pharma Company Information Table 149. Aurobindo Pharma Business Overview Table 150. Aurobindo Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 151. Aurobindo Pharma Ondansetron Product Portfolio Table 152. Aurobindo Pharma Recent Development Table 153. Zydus Lifesciences Company Information Table 154. Zydus Lifesciences Business Overview Table 155. Zydus Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 156. Zydus Lifesciences Ondansetron Product Portfolio Table 157. Zydus Lifesciences Recent Development Table 158. Lupin Company Information Table 159. Lupin Business Overview Table 160. Lupin Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 161. Lupin Ondansetron Product Portfolio Table 162. Lupin Recent Development Table 163. Hikma Pharmaceuticals Company Information Table 164. Hikma Pharmaceuticals Business Overview Table 165. Hikma Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 166. Hikma Pharmaceuticals Ondansetron Product Portfolio Table 167. Hikma Pharmaceuticals Recent Development Table 168. Fresenius Kabi Company Information Table 169. Fresenius Kabi Business Overview Table 170. Fresenius Kabi Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 171. Fresenius Kabi Ondansetron Product Portfolio Table 172. Fresenius Kabi Recent Development Table 173. Baxter Pharmaceuticals Company Information Table 174. Baxter Pharmaceuticals Business Overview Table 175. Baxter Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 176. Baxter Pharmaceuticals Ondansetron Product Portfolio Table 177. Baxter Pharmaceuticals Recent Development Table 178. North America Ondansetron Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 179. North America Ondansetron Sales by Country (2021-2026) & (kg) Table 180. North America Ondansetron Sales Market Share by Country (2021-2026) Table 181. North America Ondansetron Sales Forecast by Country (2027-2032) & (kg) Table 182. North America Ondansetron Sales Market Share Forecast by Country (2027-2032) Table 183. North America Ondansetron Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. North America Ondansetron Market Size by Country (2021-2026) & (US$ Million) Table 185. North America Ondansetron Market Share by Country (2021-2026) Table 186. North America Ondansetron Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. North America Ondansetron Market Share Forecast by Country (2027-2032) Table 188. Europe Ondansetron Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 189. Europe Ondansetron Sales by Country (2021-2026) & (kg) Table 190. Europe Ondansetron Sales Market Share by Country (2021-2026) Table 191. Europe Ondansetron Sales Forecast by Country (2027-2032) & (kg) Table 192. Europe Ondansetron Sales Market Share Forecast by Country (2027-2032) Table 193. Europe Ondansetron Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Europe Ondansetron Market Size by Country (2021-2026) & (US$ Million) Table 195. Europe Ondansetron Market Share by Country (2021-2026) Table 196. Europe Ondansetron Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Europe Ondansetron Market Share Forecast by Country (2027-2032) Table 198. Asia-Pacific Ondansetron Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 199. Asia-Pacific Ondansetron Sales by Country (2021-2026) & (kg) Table 200. Asia-Pacific Ondansetron Sales Market Share by Country (2021-2026) Table 201. Asia-Pacific Ondansetron Sales Forecast by Country (2027-2032) & (kg) Table 202. Asia-Pacific Ondansetron Sales Market Share Forecast by Country (2027-2032) Table 203. Asia-Pacific Ondansetron Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 204. Asia-Pacific Ondansetron Market Size by Country (2021-2026) & (US$ Million) Table 205. Asia-Pacific Ondansetron Market Share by Country (2021-2026) Table 206. Asia-Pacific Ondansetron Market Size Forecast by Country (2027-2032) & (US$ Million) Table 207. Asia-Pacific Ondansetron Market Share Forecast by Country (2027-2032) Table 208. Latin America Ondansetron Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 209. Latin America Ondansetron Sales by Country (2021-2026) & (kg) Table 210. Latin America Ondansetron Sales Market Share by Country (2021-2026) Table 211. Latin America Ondansetron Sales Forecast by Country (2027-2032) & (kg) Table 212. Latin America Ondansetron Sales Market Share Forecast by Country (2027-2032) Table 213. Latin America Ondansetron Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 214. Latin America Ondansetron Market Size by Country (2021-2026) & (US$ Million) Table 215. Latin America Ondansetron Market Share by Country (2021-2026) Table 216. Latin America Ondansetron Market Size Forecast by Country (2027-2032) & (US$ Million) Table 217. Latin America Ondansetron Market Share Forecast by Country (2027-2032) Table 218. Middle East and Africa Ondansetron Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 219. Middle East and Africa Ondansetron Sales by Country (2021-2026) & (kg) Table 220. Middle East and Africa Ondansetron Sales Market Share by Country (2021-2026) Table 221. Middle East and Africa Ondansetron Sales Forecast by Country (2027-2032) & (kg) Table 222. Middle East and Africa Ondansetron Sales Market Share Forecast by Country (2027-2032) Table 223. Middle East and Africa Ondansetron Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 224. Middle East and Africa Ondansetron Market Size by Country (2021-2026) & (US$ Million) Table 225. Middle East and Africa Ondansetron Market Share by Country (2021-2026) Table 226. Middle East and Africa Ondansetron Market Size Forecast by Country (2027-2032) & (US$ Million) Table 227. Middle East and Africa Ondansetron Market Share Forecast by Country (2027-2032) Table 228. Key Raw Materials Table 229. Raw Materials Key Suppliers Table 230. Ondansetron Distributors List Table 231. Ondansetron Customers List Table 232. Research Programs/Design for This Report Table 233. Authors List of This Report Table 234. Secondary Sources Table 235. Primary Sources List of Figures Figure 1. Ondansetron Image Figure 2. Global Ondansetron Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ondansetron Market Size (2021-2032) & (US$ Million) Figure 4. Global Ondansetron Sales (2021-2032) & (kg) Figure 5. Tablets (including ODT) Image Figure 6. Global Tablets (including ODT) Sales YoY Growth (2021-2032) & (kg) Figure 7. Injection Image Figure 8. Global Injection Sales YoY Growth (2021-2032) & (kg) Figure 9. ODF/OSF Image Figure 10. Global ODF/OSF Sales YoY Growth (2021-2032) & (kg) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (kg) Figure 13. Global Ondansetron Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Ondansetron Market Share by Type 2025 VS 2032 Figure 15. North America Ondansetron Sales Market Share in Volume by Type in 2025 Figure 16. North America Ondansetron Sales Market Share in Value by Type in 2025 Figure 17. Europe Ondansetron Sales Market Share in Volume by Type in 2025 Figure 18. Europe Ondansetron Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Ondansetron Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Ondansetron Sales Market Share in Value by Type in 2025 Figure 21. Latin America Ondansetron Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Ondansetron Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Ondansetron Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Ondansetron Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Ondansetron Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital pharmacies Image Figure 28. Global Hospital pharmacies Sales YoY Growth (2021-2032) & (kg) Figure 29. Retail pharmacies Image Figure 30. Global Retail pharmacies Sales YoY Growth (2021-2032) & (kg) Figure 31. Online pharmacies Image Figure 32. Global Online pharmacies Sales YoY Growth (2021-2032) & (kg) Figure 33. Global Ondansetron Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Ondansetron Market Share by Application 2025 VS 2032 Figure 35. North America Ondansetron Sales Market Share in Volume by Application in 2025 Figure 36. North America Ondansetron Sales Market Share in Value by Application in 2025 Figure 37. Europe Ondansetron Sales Market Share in Volume by Application in 2025 Figure 38. Europe Ondansetron Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Ondansetron Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Ondansetron Sales Market Share in Value by Application in 2025 Figure 41. Latin America Ondansetron Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Ondansetron Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Ondansetron Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Ondansetron Sales Market Share in Value by Application in 2025 Figure 45. North America Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 46. North America Ondansetron Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Ondansetron Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Ondansetron Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 50. Europe Ondansetron Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Ondansetron Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Ondansetron Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 54. Asia-Pacific Ondansetron Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Ondansetron Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Ondansetron Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 58. Latin America Ondansetron Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Ondansetron Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Ondansetron Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 62. Middle East and Africa Ondansetron Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Ondansetron Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Ondansetron Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Ondansetron Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Ondansetron Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets (including ODT)
  • Injection
  • ODF/OSF
  • Other
Applications
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
Companies covered
  • Sun Pharmaceuticals
  • Sandoz
  • Qilu Pharmaceutical
  • Fuan Pharmaceutical
  • PKU HealthCare
  • Wockhardt
  • Aelida Healthcare
  • Beijing Sciecure Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Fosun Pharma
  • Harbin Medisan
  • CTX Lifesciences
  • Pfizer
  • Viatris
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Zydus Lifesciences
  • Lupin
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Baxter Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ondansetron Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Ondansetron Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Ondansetron Market by Type
  6. 1.3.1 Tablets (including ODT)
  7. 1.3.2 Injection
  8. 1.3.3 ODF/OSF
  9. 1.3.4 Other
  10. 1.4 Global Ondansetron Market Size by Type
  11. 1.4.1 Global Ondansetron Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Ondansetron Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Ondansetron Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Ondansetron Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Ondansetron Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Ondansetron Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Ondansetron Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Ondansetron Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Ondansetron Industry Trends
  2. 2.2 Ondansetron Industry Drivers
  3. 2.3 Ondansetron Industry Opportunities and Challenges
  4. 2.4 Ondansetron Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Ondansetron Revenue (2021-2026)
  2. 3.2 Global Top Players by Ondansetron Sales (2021-2026)
  3. 3.3 Global Top Players by Ondansetron Price (2021-2026)
  4. 3.4 Global Ondansetron Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ondansetron Major Company Production Sites & Headquarters
  6. 3.6 Global Ondansetron Company, Product Type & Application
  7. 3.7 Global Ondansetron Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ondansetron Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ondansetron Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ondansetron Tier 1, Tier 2, and Tier 3
4 Ondansetron Regional Status and Outlook
  1. 4.1 Global Ondansetron Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Ondansetron Historic Market Size by Region
  3. 4.2.1 Global Ondansetron Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Ondansetron Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Ondansetron Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Ondansetron Forecasted Market Size by Region
  7. 4.3.1 Global Ondansetron Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Ondansetron Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Ondansetron Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Ondansetron by Application
  1. 5.1 Ondansetron Market by Application
  2. 5.1.1 Hospital pharmacies
  3. 5.1.2 Retail pharmacies
  4. 5.1.3 Online pharmacies
  5. 5.2 Global Ondansetron Market Size by Application
  6. 5.2.1 Global Ondansetron Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Ondansetron Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Ondansetron Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Ondansetron Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Ondansetron Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Ondansetron Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Ondansetron Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Ondansetron Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sun Pharmaceuticals
  2. 6.1.1 Sun Pharmaceuticals Company Information
  3. 6.1.2 Sun Pharmaceuticals Business Overview
  4. 6.1.3 Sun Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sun Pharmaceuticals Ondansetron Product Portfolio
  6. 6.1.5 Sun Pharmaceuticals Recent Developments
  7. 6.2 Sandoz
  8. 6.2.1 Sandoz Company Information
  9. 6.2.2 Sandoz Business Overview
  10. 6.2.3 Sandoz Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sandoz Ondansetron Product Portfolio
  12. 6.2.5 Sandoz Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical Ondansetron Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Fuan Pharmaceutical
  20. 6.4.1 Fuan Pharmaceutical Company Information
  21. 6.4.2 Fuan Pharmaceutical Business Overview
  22. 6.4.3 Fuan Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Fuan Pharmaceutical Ondansetron Product Portfolio
  24. 6.4.5 Fuan Pharmaceutical Recent Developments
  25. 6.5 PKU HealthCare
  26. 6.5.1 PKU HealthCare Company Information
  27. 6.5.2 PKU HealthCare Business Overview
  28. 6.5.3 PKU HealthCare Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 PKU HealthCare Ondansetron Product Portfolio
  30. 6.5.5 PKU HealthCare Recent Developments
  31. 6.6 Wockhardt
  32. 6.6.1 Wockhardt Company Information
  33. 6.6.2 Wockhardt Business Overview
  34. 6.6.3 Wockhardt Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Wockhardt Ondansetron Product Portfolio
  36. 6.6.5 Wockhardt Recent Developments
  37. 6.7 Aelida Healthcare
  38. 6.7.1 Aelida Healthcare Company Information
  39. 6.7.2 Aelida Healthcare Business Overview
  40. 6.7.3 Aelida Healthcare Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Aelida Healthcare Ondansetron Product Portfolio
  42. 6.7.5 Aelida Healthcare Recent Developments
  43. 6.8 Beijing Sciecure Pharmaceutical
  44. 6.8.1 Beijing Sciecure Pharmaceutical Company Information
  45. 6.8.2 Beijing Sciecure Pharmaceutical Business Overview
  46. 6.8.3 Beijing Sciecure Pharmaceutical Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio
  48. 6.8.5 Beijing Sciecure Pharmaceutical Recent Developments
  49. 6.9 Jiangsu Hengrui Pharmaceuticals
  50. 6.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 6.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 6.9.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio
  54. 6.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 6.10 Fosun Pharma
  56. 6.10.1 Fosun Pharma Company Information
  57. 6.10.2 Fosun Pharma Business Overview
  58. 6.10.3 Fosun Pharma Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Fosun Pharma Ondansetron Product Portfolio
  60. 6.10.5 Fosun Pharma Recent Developments
  61. 6.11 Harbin Medisan
  62. 6.11.1 Harbin Medisan Company Information
  63. 6.11.2 Harbin Medisan Business Overview
  64. 6.11.3 Harbin Medisan Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Harbin Medisan Ondansetron Product Portfolio
  66. 6.11.5 Harbin Medisan Recent Developments
  67. 6.12 CTX Lifesciences
  68. 6.12.1 CTX Lifesciences Company Information
  69. 6.12.2 CTX Lifesciences Business Overview
  70. 6.12.3 CTX Lifesciences Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 CTX Lifesciences Ondansetron Product Portfolio
  72. 6.12.5 CTX Lifesciences Recent Developments
  73. 6.13 Pfizer
  74. 6.13.1 Pfizer Company Information
  75. 6.13.2 Pfizer Business Overview
  76. 6.13.3 Pfizer Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Pfizer Ondansetron Product Portfolio
  78. 6.13.5 Pfizer Recent Developments
  79. 6.14 Viatris
  80. 6.14.1 Viatris Company Information
  81. 6.14.2 Viatris Business Overview
  82. 6.14.3 Viatris Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Viatris Ondansetron Product Portfolio
  84. 6.14.5 Viatris Recent Developments
  85. 6.15 Dr. Reddy's Laboratories
  86. 6.15.1 Dr. Reddy's Laboratories Company Information
  87. 6.15.2 Dr. Reddy's Laboratories Business Overview
  88. 6.15.3 Dr. Reddy's Laboratories Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Dr. Reddy's Laboratories Ondansetron Product Portfolio
  90. 6.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 6.16 Aurobindo Pharma
  92. 6.16.1 Aurobindo Pharma Company Information
  93. 6.16.2 Aurobindo Pharma Business Overview
  94. 6.16.3 Aurobindo Pharma Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Aurobindo Pharma Ondansetron Product Portfolio
  96. 6.16.5 Aurobindo Pharma Recent Developments
  97. 6.17 Zydus Lifesciences
  98. 6.17.1 Zydus Lifesciences Company Information
  99. 6.17.2 Zydus Lifesciences Business Overview
  100. 6.17.3 Zydus Lifesciences Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Zydus Lifesciences Ondansetron Product Portfolio
  102. 6.17.5 Zydus Lifesciences Recent Developments
  103. 6.18 Lupin
  104. 6.18.1 Lupin Company Information
  105. 6.18.2 Lupin Business Overview
  106. 6.18.3 Lupin Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Lupin Ondansetron Product Portfolio
  108. 6.18.5 Lupin Recent Developments
  109. 6.19 Hikma Pharmaceuticals
  110. 6.19.1 Hikma Pharmaceuticals Company Information
  111. 6.19.2 Hikma Pharmaceuticals Business Overview
  112. 6.19.3 Hikma Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Hikma Pharmaceuticals Ondansetron Product Portfolio
  114. 6.19.5 Hikma Pharmaceuticals Recent Developments
  115. 6.20 Fresenius Kabi
  116. 6.20.1 Fresenius Kabi Company Information
  117. 6.20.2 Fresenius Kabi Business Overview
  118. 6.20.3 Fresenius Kabi Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Fresenius Kabi Ondansetron Product Portfolio
  120. 6.20.5 Fresenius Kabi Recent Developments
  121. 6.21 Baxter Pharmaceuticals
  122. 6.21.1 Baxter Pharmaceuticals Company Information
  123. 6.21.2 Baxter Pharmaceuticals Business Overview
  124. 6.21.3 Baxter Pharmaceuticals Ondansetron Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Baxter Pharmaceuticals Ondansetron Product Portfolio
  126. 6.21.5 Baxter Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Ondansetron Sales by Country
  2. 7.1.1 North America Ondansetron Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Ondansetron Sales by Country (2021-2026)
  4. 7.1.3 North America Ondansetron Sales Forecast by Country (2027-2032)
  5. 7.2 North America Ondansetron Market Size by Country
  6. 7.2.1 North America Ondansetron Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Ondansetron Market Size by Country (2021-2026)
  8. 7.2.3 North America Ondansetron Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Ondansetron Sales by Country
  2. 8.1.1 Europe Ondansetron Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Ondansetron Sales by Country (2021-2026)
  4. 8.1.3 Europe Ondansetron Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Ondansetron Market Size by Country
  6. 8.2.1 Europe Ondansetron Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Ondansetron Market Size by Country (2021-2026)
  8. 8.2.3 Europe Ondansetron Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Ondansetron Sales by Country
  2. 9.1.1 Asia-Pacific Ondansetron Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Ondansetron Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Ondansetron Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Ondansetron Market Size by Country
  6. 9.2.1 Asia-Pacific Ondansetron Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Ondansetron Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Ondansetron Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Ondansetron Sales by Country
  2. 10.1.1 South America Ondansetron Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Ondansetron Sales by Country (2021-2026)
  4. 10.1.3 South America Ondansetron Sales Forecast by Country (2027-2032)
  5. 10.2 South America Ondansetron Market Size by Country
  6. 10.2.1 South America Ondansetron Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Ondansetron Market Size by Country (2021-2026)
  8. 10.2.3 South America Ondansetron Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Ondansetron Sales by Country
  2. 11.1.1 Middle East and Africa Ondansetron Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Ondansetron Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Ondansetron Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Ondansetron Market Size by Country
  6. 11.2.1 Middle East and Africa Ondansetron Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Ondansetron Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Ondansetron Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Ondansetron Value Chain Analysis
  2. 12.1.1 Ondansetron Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Ondansetron Production Mode & Process
  7. 12.2 Ondansetron Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Ondansetron Distributors
  10. 12.2.3 Ondansetron Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst